linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Strategy

It wasn’t a one-horse race. We chose Carlyle because of its experience in healthcare: Ajay Piramal

The Piramal Enterprises chairman recently said global private-equity major Carlyle Group would pick up a 20% stake in its pharmaceutical unit for INR3,700 crore.
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
vikasdandekar1
3 Jul 2020 5 Mins Read 2 comments
From left, Nandini Piramal, executive director, and Ajay Piramal, chairman, Piramal Enterprises; photo by Bharat Chanda
From left, Nandini Piramal, executive director, and Ajay Piramal, chairman, Piramal Enterprises; photo by Bharat Chanda
Ajay Piramal is an intrepid businessman. He has acquired businesses, grown them, and sold them off at hefty valuations. His decision to diversify into financial services helped transform Piramal Group into a conglomerate. However, the billionaire businessman still holds pharmaceuticals close to his heart. In an exclusive chat with Vikas Dandekar of ET Prime, Ajay Piramal and his daughter
everything. Now, we can do acquisitions. It is clear that if we don’t build relationships, valuations will come down. Any growth forecasts? Ajay Piramal: We are not giving any now, but will share it at the right time. There are a lot of regulatory approvals we need to close and then figure out the way forward.
Ajay Piramal is an intrepid businessman. He has acquired businesses, grown them, and sold them off at hefty valuations. His decision to diversify into financial services helped transform Piramal Group into a conglomerate. However, the billionaire businessman still holds pharmaceuticals close to his heart. In an exclusive chat with Vikas Dandekar of ET Prime, Ajay Piramal and his daughter everything. Now, we can do acquisitions. It is clear that if we don’t build relationships, valuations will come down. Any growth forecasts? Ajay Piramal: We are not giving any now, but will share it at the right time. There are a lot of regulatory approvals we need to close and then figure out the way forward.

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

CONTRIBUTORS WHO HAVE COMMENTED ON THIS STORY

test

user Vikas Dandekar ET Prime, Editor - Pharma and Life Sciences

test

user Sriram J

Current Edition

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]